1. Home
  2. BOLT vs JZ Comparison

BOLT vs JZ Comparison

Compare BOLT & JZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

HOLD

Current Price

$3.89

Market Cap

7.1M

Sector

Health Care

ML Signal

HOLD

Logo Jianzhi Education Technology Group Company Limited

JZ

Jianzhi Education Technology Group Company Limited

HOLD

Current Price

$2.19

Market Cap

6.6M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOLT
JZ
Founded
2015
2011
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
6.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
BOLT
JZ
Price
$3.89
$2.19
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$34.00
N/A
AVG Volume (30 Days)
23.8K
1.8M
Earning Date
05-13-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,695,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$133.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.07
N/A
52 Week Low
$3.13
$0.09
52 Week High
$7.20
$5.46

Technical Indicators

Market Signals
Indicator
BOLT
JZ
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
BOLT
JZ

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

About JZ Jianzhi Education Technology Group Company Limited

Jianzhi Education Technology Group Co Ltd engages in developing educational content to fulfill the massive demand for high-quality, professional development training resources in China. The company and its subsidiaries VIE and VIEs generate subscription revenue through selling subscriptions to online learning platforms, higher education institutions, and other institutional customers under a B2B2C model mainly through the platform of Sentu Academy; offering subscriptions concerning educational content in mobile video packages directly to end users under a B2C model through the platforms such as Fish Learning or Light Class, etc. It has single operating segment: Educational content services and other services and IT-related solution services.

Share on Social Networks: